STATEMENT OF NEED/TARGET AUDIENCE

Approximately 40,000 new cases of renal cell cancer (RCC) occur annually, with 13,000 deaths due to the disease. Recently, an increased understanding of the biology of RCC and emerging clinical trial results have led to new therapeutic options for patients. To bridge the gap between research and patient care, Renal Cell Cancer Update utilizes one-on-one interviews with leading oncology investigators. By providing access to expert perspectives on the latest research developments in the context of clinical practice, this CME activity will assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date management strategies for patients with RCC.

LEARNING OBJECTIVES

• Apply an understanding of the biology underlying clear cell RCC, including inactivation of the von Hippel- Lindau (VHL) tumor suppressor gene and the pathway leading to VEGF overexpression, to therapeutic decision-making.
• Construct management strategies for patients with advanced RCC, considering safety and efficacy profiles for targeted biologic therapies inhibiting VEGF, PDGF and EGF receptors.
• Evaluate the impact of pathologic grade on the selection of therapies and clinical outcomes in RCC, assess molecular targets believed to have clinical relevance in RCC and apply this information to clinical practice.
• Develop a therapeutic approach for the sequencing and duration of treatment with targeted biologic therapies for patients with RCC.
• Counsel appropriately selected patients about participation in clinical trials in the adjuvant and metastatic settings.

PURPOSE OF THIS ISSUE OF RENAL CELL CANCER UPDATE

The purpose of Issue 1 of Renal Cell Cancer Update is to support the learning objectives by offering the perspectives of Drs Motzer, George, Amato and Dutcher on the integration of emerging clinical research data into the management of renal cell cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains both audio and print components. To receive credit, the participant should listen to the CDs, review the monograph and complete the Post-test and Educational Assessment and Credit Form located in the back of this monograph or on our website. This monograph contains edited comments, clinical trial schemas, graphics and references that supplement the audio program. RenalCellCancerUpdate.com includes an easyto- use, interactive version of this monograph with links to relevant full-text articles, abstracts, trial information and other web resources indicated here in blue underlined text.

This program is supported by educational grants from Bayer Pharmaceuticals Corporation/ Onyx Pharmaceuticals Inc and Genentech BioOncology.

Home

Editor
Neil Love, MD

Interviews

Robert J Motzer, MD
- Select publications

Daniel J George, MD
- Select publications

Robert J Amato, DO
- Select publications

Janice P Dutcher, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office